References
American Diabetes Association (2013) Standards of medical care in diabetes 2013. Diabetes Care 36(Suppl 1):S11–S66. doi:10.2337/dc13-S011
Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S, ONTARGET investigators (2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372:547–553. doi:10.1016/S0140-6736(08)61236-2
Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA (2009) Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 24:1663–1671. doi:10.1093/ndt/gfn721
Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O’Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P, VA NEPHRON-D Investigators (2013) Combined angiotensin inhibition for the treatment of diabetic nephropathy. NEJM 369:1892–1903. doi:10.1056/NEJMoa1303154
Conflict of interest
None.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Wu, M.A., Perego, F. & Gruppo di Autoformazione Metodologica (GrAM). Is dual RAAS blockade useful in diabetic nephropathy?. Intern Emerg Med 9, 589–591 (2014). https://doi.org/10.1007/s11739-014-1075-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11739-014-1075-6